10 years of historical data (2015–2024) · Healthcare · Biotechnology
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Spero Therapeutics, Inc. currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $122M | $56M | $78M | $65M | $495M | $434M | $175M | $98M | $30M | — | — |
| Enterprise Value | $74M | $7M | $7M | $-37437820 | $389M | $357M | $151M | $64M | $-56892336 | — | — |
| P/E Ratio → | -1.71 | — | 3.42 | — | — | — | — | — | — | — | — |
| P/S Ratio | 2.55 | 1.16 | 0.75 | 1.34 | 161.12 | 46.52 | 9.63 | 24.81 | 15.36 | — | — |
| P/B Ratio | 2.54 | 1.21 | 0.73 | 0.86 | 5.60 | 3.29 | 2.34 | 0.85 | 0.36 | — | — |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 0.15 | 0.07 | -0.77 | 126.84 | 38.23 | 8.29 | 16.22 | -28.75 | — | — |
| EV / EBITDA | — | — | 0.33 | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | 0.27 | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Spero Therapeutics, Inc. earns an operating margin of -152.9%. Operating margins have compressed from -86.9% to -152.9% over the past 3 years, signaling potential cost pressures or competitive headwinds. A negative ROE of -89.6% indicates the company is currently destroying shareholder equity.
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | -101.7% | -101.7% | 50.4% | 100.0% | 100.0% | -618.1% | -262.5% | -754.4% | -1560.9% | -7760.6% | — |
| Operating Margin | -152.9% | -152.9% | 20.7% | -86.9% | -2865.5% | -847.9% | -348.4% | -1079.3% | -2108.6% | -9916.7% | — |
| Net Profit Margin | -142.9% | -142.9% | 22.0% | -95.5% | -2923.6% | -839.0% | -335.7% | -1050.5% | -2329.3% | -7609.3% | — |
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -89.6% | -89.6% | 24.9% | -56.5% | -81.5% | -75.8% | -63.9% | -41.3% | -100.6% | -835.2% | — |
| ROA | -46.8% | -46.8% | 14.8% | -31.4% | -55.3% | -60.3% | -51.8% | -37.5% | -86.0% | -243.4% | -141.5% |
| ROIC | -327.2% | -327.2% | 336.4% | — | -349.9% | -113.0% | -71.6% | -80.1% | — | — | — |
| ROCE | -71.0% | -71.0% | 17.3% | -33.0% | -60.4% | -72.4% | -64.5% | -42.4% | -90.5% | -873.2% | -1765.2% |
Solvency and debt-coverage ratios — lower is generally safer
The company holds a net cash position — cash of $53M exceeds total debt of $4M, providing substantial financial flexibility for buybacks, acquisitions, or weathering downturns.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.09 | 0.09 | 0.05 | 0.09 | 0.08 | 0.06 | 0.07 | — | — | — | — |
| Debt / EBITDA | — | — | 0.25 | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -1.05 | -0.66 | -1.35 | -1.19 | -0.59 | -0.32 | -0.29 | -1.02 | -1.62 | — |
| Net Debt / EBITDA | — | — | -3.24 | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — | — | — | — |
| Interest Coverage | — | — | — | -16.20 | -45.35 | — | — | -141.27 | -137.72 | — | — |
Net cash position: cash ($53M) exceeds total debt ($4M)
Short-term solvency ratios and asset-utilisation metrics
Spero Therapeutics, Inc.'s current ratio of 2.19x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The current ratio has declined from 5.04x to 2.19x over the past 3 years.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 2.19 | 2.19 | 3.53 | 5.04 | 8.46 | 9.70 | 3.58 | 9.37 | 10.70 | 1.72 | 0.93 |
| Quick Ratio | 2.19 | 2.19 | 3.53 | 5.25 | 8.46 | 9.70 | 3.58 | 10.08 | 11.29 | 1.72 | 0.93 |
| Cash Ratio | 1.08 | 1.08 | 2.05 | 5.04 | 7.84 | 8.85 | 3.08 | 9.37 | 10.70 | 1.49 | 0.89 |
| Asset Turnover | — | 0.43 | 0.57 | 0.39 | 0.02 | 0.06 | 0.17 | 0.03 | 0.02 | 0.02 | — |
| Inventory Turnover | — | — | — | — | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | 399.23 | 178.30 | 8.14 | 314.00 | — | 206.08 | 119.46 | 542.80 | 331.22 | — |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Spero Therapeutics, Inc. does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business.
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | 29.3% | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — |
| Shares Outstanding | — | $54M | $53M | $38M | $31M | $22M | $18M | $16M | $3M | $7M | $7M |
Compare SPRO with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
| SPROYou | $122M | -1.7 | — | — | -101.7% | -152.9% | -89.6% | -327.2% | — |
| BNTX | $28B | -33.7 | — | — | 80.3% | -47.8% | -3.4% | -10.5% | — |
| MRNA | $21B | -5.8 | — | — | 54.2% | -123.3% | -28.8% | -27.0% | — |
| SMMT | $13B | -11.5 | — | — | — | — | -206.1% | -163.4% | — |
| PCVX | $8B | -11.0 | — | — | — | — | -25.6% | -24.7% | — |
| CDTX | $7B | -8.3 | — | — | 100.0% | -13811.9% | -219.0% | — | — |
| SCNI | $3B | 0.1 | — | — | -88.1% | -1312.8% | 177.4% | -61.1% | — |
| NVAX | $2B | 3.9 | 3.7 | — | 93.5% | 40.3% | — | — | 0.5 |
| VIR | $1B | -2.9 | — | — | 82.9% | -682.7% | -45.7% | -40.3% | — |
| CVAC | $1B | 6.5 | 3.1 | 12.6 | 80.2% | 33.2% | 26.7% | 65.0% | 0.2 |
| VALN | $963M | -55.3 | 26.3 | — | 41.9% | 7.9% | -7.9% | 4.5% | 6.6 |
| Healthcare Median | — | 23.7 | 13.8 | 18.8 | 65.8% | -6.3% | -37.3% | -15.0% | 3.1 |
Peers based on L4 peer group classification. Compare multiple stocks →
Includes 30+ ratios · 10 years · Updated daily
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorSee our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationSee how SPRO stacks up against sector leader BioNTech SE.
Start ComparisonSpero Therapeutics, Inc.'s current P/E ratio is -1.7x. The historical average is 3.4x.
Spero Therapeutics, Inc.'s return on equity (ROE) is -89.6%. The historical average is -60.5%.
Based on historical data, Spero Therapeutics, Inc. is trading at a P/E of -1.7x. Compare with industry peers and growth rates for a complete picture.
Spero Therapeutics, Inc. has -101.7% gross margin and -152.9% operating margin.